期刊文献+

紫杉醇脂质体对乳腺癌MCF-7细胞生长抑制作用的机制 被引量:7

Mechanism of Paclitaxel Liposome Inhibitory Action on Breast Cancer Cell
下载PDF
导出
摘要 目的分析紫杉醇脂质体对乳腺癌MCF-7细胞的生长抑制作用,观察药物作用的时间浓度关系并探究其作用机制。方法应用不同剂量紫杉醇脂质体对MCF-7细胞进行处理,通过MTT法检测细胞存活率,倒置显微镜观察细胞形态,流式细胞分析技术检测细胞凋亡情况及其对细胞周期的影响,Western blot法检测bcl-2蛋白表达情况。结果紫杉醇脂质体对MCF-7细胞有明显的剂量-时间依赖效应。紫杉醇与紫杉醇脂质体均可将MCF-7细胞阻滞在G2/M期,且随药物浓度增加,凋亡细胞所占比例逐渐增加。通过Western blot法检测发现,紫杉醇脂质体作用后MCF-7细胞bcl-2蛋白表达明显下降,bax蛋白表达明显上调,bax/bcl-2比例明显上调。结论与紫杉醇相比,紫杉醇以脂质体对人乳腺癌MCF-7细胞具有同样的抑制作用,其促凋亡机制之一为调控bcl-2及bax蛋白表达。 Objective To study the inhibitory action of paclitaxel liposome to breast cancer cell(MCF-7) and analyze the mechanism through detecting the time-concentration effect of paclitaxel liposome.Methods MCF-7 cells were cultured and treated with different concentration of paclitaxel liposome.The cell viability was analyzed by MTT.Cell morphology was observed inverted microscope.Cell apoptosis and cell cycle arrest status were detected by flow cytometry.The expressions of bcl-2 and bax proteins were detected by Western blot Results The paclitaxel liposome could inhibit MCF-7 cells by time and concentration-dependent effect.The paclitaxel and paclitaxel liposome could block MCF-7 cells at G2/M phase,and cell apoptosis was more obvious along with drug concentration increasing.The Western blots results demonstrated that after using paclitaxel liposome,the expression of bcl-2 protein was obviously decreased,while the expression of bax protein increased.The value of bax/bcl-2 was up-regulated.Conclusion Compared with paclitaxel,paclitaxel liposome can similarly inhibit MCF-7 cells.One of the pro-apoptotic mechanisms is regulating the expression of bcl-2 and bax.
出处 《肿瘤防治研究》 CAS CSCD 北大核心 2013年第2期138-143,共6页 Cancer Research on Prevention and Treatment
基金 天津市科技计划资助项目(10JCYBJC11500) 长江学者和创新团队发展计划资助项目(IRT0743)
关键词 紫杉醇脂质体 乳腺癌 生长抑制 Paclitaxel liposome Breast cancer Inhibitory action
  • 相关文献

参考文献17

  • 1Damen EW,Nevalainen TJ,van den Bergh TJ. Synthesis of novel paclitaxel prodrus desined for bioreductive activation in hypoxic tumour tissue[J].Bioor Med Chem,2002,(01):71-74.
  • 2Lahat G,Dhuka AR,Lahat S. Outcome of locally recurrent and metastatic angiosarcoma[J].Annals of Surgical Oncology,2009,(09):2502-2509.doi:10.1245/s10434-009-0569-3.
  • 3Huan CH,Millenson MM,Sherman EJ. Promisin survival in patients with recurrent non-small cell lung cancer treated with docetaxel and emcitabine in combination as second-line therapy[J].JOURNAL OF THORACIC ONCOLOGY,2008,(09):1032-1038.
  • 4Sasada S,Ninomiya M,Kobayashi J. A case of lon surviv al of a scirrhous astric cancer patient with esophaeal invasion and peritoneal dissemination throuh chemotherapy and pallia tive surgery[J].Gan to Kagaku Ryoho(Japanese Journal of Cancer and Chemotherapy),2008,(09):1551-1554.
  • 5Castells M. Rapid desensitization of hypersensitivity reactions to chemotherapy aents[J].Curr Drug Saf,2006,(03):243-251.
  • 6张晓静,张频.紫杉醇新剂型的开发及临床研究进展[J].癌症进展,2007,5(1):66-72. 被引量:57
  • 7张燕,董建红.紫杉醇抗肿瘤作用机制研究现状[J].现代中西医结合杂志,2005,14(24):3312-3313. 被引量:7
  • 8Hong RL,Lin CH,Chao TY. A phase Ⅰ study evaluatin the combination of peylated liposomal doxorubicin and paclitaxel as salvae chemotherapy in metastatic breast cancer previously treated with anthracycline[J].Cancer Chemotherapy and Pharmacology,2008,(05):847-853.
  • 9Dhanikula RS,Dhanikula AB,Panchanula R. Thermore versible liposomal poloxamerel for the delivery of paclitaxel:dose proportionality and hematoloical toxicity studies[J].Die Pharmazie,2008,(06):439-445.
  • 10Marupudi NI,Han JE,Li KW. Paclitaxel:a review of adverse toxicities and novel delivery strateies[J].Expert Opinion Drug Safety,2007,(05):609-621.

二级参考文献55

共引文献70

同被引文献91

  • 1张炜,崔洪尊,嵇振岭.紫杉醇对人胃癌细胞SGC-7901增殖及凋亡的影响[J].现代肿瘤医学,2008,16(11):1870-1872. 被引量:2
  • 2中国抗癌协会乳腺癌专业委员会.中国抗癌协会乳腺癌诊治指南与规范(2011版)[J].中国癌症杂志,2011,21(5):367-417. 被引量:264
  • 3仝新勇,周建平,谭燕,吴春勇,林文垚,刘馨.紫杉醇纳米脂质体在大鼠体内的药动学[J].中国医院药学杂志,2006,26(6):677-679. 被引量:10
  • 4张晓静,张频.紫杉醇新剂型的开发及临床研究进展[J].癌症进展,2007,5(1):66-72. 被引量:57
  • 5Ferlay J,Shin HR,Bray F,et al.Cancer incidence and mortality worldwide[M].Lyon,France:International Agency for Research on Cancer,2010:1.
  • 6Llombart-Cussac A,Martin M,Harbeck N,et al.A randomized,double-blind,phase Ⅱ study of two doses of pemetrexed as first-line chemotherapy for advanced breast cancer[J].Clin Cancer Res,2007,13(12):3652-3659.
  • 7Blasinska-Morawiec M,Martin M,Salas F,et al.A phase Ⅱ study of pemetrexed and doxombicin in patients with advanced or metastatic breast cancer(MBC)[J].J Clin Oncol,2007,25(18):1047.
  • 8Maedeh K,Moftakhari Ei,Ebrahim A,et al.Cytotoxicity of liposomal paclitaxel in breast cancer cell line MCF-7[J].Ind J Clin Biochem,2013,28(4):358-360.
  • 9Wei Y,Xue Z,Ye Y,et al.Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation[J].Biomed Chromatogr,2014,28:204-212.
  • 10Donna S,Theodore S.Anti-metabolite radiosensitizers [J].J Clin Oncol,2007,25(26):4043-4050.

引证文献7

二级引证文献13

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部